Your browser doesn't support javascript.
The SARS-CoV-2 inactivated vaccine enhances the broad neutralization against variants in individuals recovered from COVID-19 up to one year.
Zhang, Zheng; Ju, Bin; Zhou, Xinrong; Cheng, Lin; Wang, Haiyan; Liao, Xuejiao; Wang, Miao; Wei, Lanlan; Song, Shuo; Zhou, Bing; Ma, Zhenghua; Guo, Huimin; Ge, Xiangyang.
  • Zhang Z; Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
  • Ju B; Guangdong Key Laboratory for Anti-Infection Drug Quality Evaluation, Shenzhen, People's Republic of China.
  • Zhou X; Shenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, Shenzhen, People's Republic of China.
  • Cheng L; Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
  • Wang H; Guangdong Key Laboratory for Anti-Infection Drug Quality Evaluation, Shenzhen, People's Republic of China.
  • Liao X; Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
  • Wang M; Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
  • Wei L; Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
  • Song S; Follow-up Department of Chronic Diseases, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
  • Zhou B; Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
  • Ma Z; Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
  • Guo H; Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
  • Ge X; Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Emerg Microbes Infect ; 11(1): 753-756, 2022 12.
Article in English | MEDLINE | ID: covidwho-1699148

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: Emerg Microbes Infect Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: Emerg Microbes Infect Year: 2022 Document Type: Article